Home › Research › Treatments
Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease
Lilienfeld S.. CNS drug reviews, 2002-01-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
It is extensively metabolized in numerous pathways, mainly in the liver via cytochrome P450 enzymes CYP2D6 and CYP3A4, and has a low potential for clinically significant drug-drug interactions. During four large randomized, double-blind, placebo-controlled trials of up to 6 months duration, galantamine 16 and 24 mg/day significantly benefited cognitive and global function, ability to perform activities of daily living (ADL) and behavior, relative to placebo and baseline, for up to 6 months. These benefits were maximized by early and continued galantamine treatment and, again, were associated with significant reductions in caregiver burden. Trials of the efficacy of galantamine in dementia related to cerebrovascular disease have also yielded positive results. There are no safety concerns associated with the use of galantamine. Galantamine may, therefore, help to reduce the overall burden and cost involved in caring for dementia patients.
What this study adds
Evidence grade: High
This is a narrative review. In four large randomized trials of up to 6 months, galantamine 16 and 24 mg/day improved cognitive and global function, activities of daily living, and behavior compared with placebo in people with Alzheimer's disease. These benefits were maximized by early and continued treatment and were associated with reduced caregiver burden, but the drug does not cure or prevent the disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Lilienfeld, S. (2002). Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS drug reviews. https://doi.org/10.1111/j.1527-3458.2002.tb00221.x
Vancouver
Lilienfeld S. Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS drug reviews. 2002. doi:10.1111/j.1527-3458.2002.tb00221.x. PMID: 12177686.
BibTeX
@article{lilienfeld2002-12177686,
author = {Lilienfeld, S.},
title = {{Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease}},
journal = {CNS drug reviews},
year = {2002},
doi = {10.1111/j.1527-3458.2002.tb00221.x},
pmid = {12177686},
url = {https://doi.org/10.1111/j.1527-3458.2002.tb00221.x}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- It is extensively metabolized in numerous pathways, mainly in the liver via cytochrome P450 enzymes CYP2D6 and CYP3A4, and has a low potential for clinically significant drug-drug interactions.
- During four large randomized, double-blind, placebo-controlled trials of up to 6 months duration, galantamine 16 and 24 mg/day significantly benefited cognitive and global function, ability to perform activities of daily living (ADL) and behavior, relative to placebo and baseline, for up to 6 months.
- These benefits were maximized by early and continued galantamine treatment and, again, were associated with significant reductions in caregiver burden.
- Trials of the efficacy of galantamine in dementia related to cerebrovascular disease have also yielded positive results.
- There are no safety concerns associated with the use of galantamine.
Why it matters
In four large randomized trials of up to 6 months, galantamine 16 and 24 mg/day improved cognitive and global function, activities of daily living, and behavior compared with placebo in people with Alzheimer's disease. These benefits were maximized by early and continued treatment and were associated with reduced caregiver burden, but the drug does not cure or prevent the disease.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthHigh
How this study scored 44/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on institution's track record, so that was left out: it earned 43 of the 97 points we could judge it on, which is 44 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (CNS drug reviews) |
| Journal's citation record | 0 / 4 | CNS Drug Reviews: journal h-index 70 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2002 — older than 20 years, still counted |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 6 / 7 | Cited 311 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 12.0 citations a year over 26 year(s) since 2002 |
| Impact for its field and year | 3 / 6 | Cited 4.3× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 3 other studies in this library |
| Still being cited | 3 / 4 | Cited 58 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Sean Lilienfeld: h-index 15 (OpenAlex, whole career) |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 12177686) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 43 / 97 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 43 of the 97 points we could judge it on is 44 out of 100. |
| Total | 44 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1111/j.1527-3458.2002.tb00221.x
- PubMed: 12177686
- Original source →
- Free full text: PubMed Central →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
3 studies in the alzhub library list this one in their references.
Related studies in Treatments from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.